You are here

  • Home
  • Online First
  • Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients

Article info

Article menu
Download PDFPDF
Original research
Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients

Authors

  1. Correspondence to Dr Emmanuel Khalifa, Biopathology, Institut Bergonié, Bordeaux 33000, France; e.khalifa{at}bordeaux.unicancer.fr
View Full Text

Citation

Khalifa E, Chapusot C, Tournier B, et al
Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients
Journal of Clinical Pathology Published Online First: 12 July 2022. doi: 10.1136/jcp-2022-208325

Publication history

  • Received April 13, 2022
  • Accepted June 28, 2022
  • First published July 12, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.